12:00 AM
Nov 05, 2012
 |  BioCentury  |  Emerging Company Profile

Atreca: Sequencing B cells

Atreca sequences B cells for antibodies; partnered with Gates for vaccines

Atreca Inc. is using high throughput B cell sequencing to identify and develop therapeutic antibodies, The company's technology is able to identify thousands of individual patient antibodies faster than techniques that require the use of cell culture.

Its first focus is vaccines, where it is working with the Bill & Melinda Gates Foundation.

Atreca is built on technology developed in the lab of co-founder William Robinson, associate professor of medicine at Stanford University. Robinson and his former graduate student and Atreca co-founder and Chief Technologist Yann Chong Tan developed a method for high throughput isolation, labeling and sequencing of single B cells.

"If you really want to capture the antibodies being made in an immune response, you need to work at the single cell level, interrogate single B cells, and find the sequence of the heavy and light...

Read the full 685 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >